Sunshine Guojian




Mega Lifesciences
Concise Prescribing Info
As monotherapy or in combination w/ methotrexate (MTX) for reducing signs & symptoms, inducing major clinical response, inhibiting progression of structural damage, & improving physical function in patients w/ moderately to severely active RA. In combination w/ MTX for reducing signs & symptoms, inhibiting progression of structural damage of active arthritis, & improving physical function in patients w/ psoriatic arthritis (PsA) who do not respond adequately to MTX alone. Reducing signs & symptoms in patients w/ active ankylosing spondylitis (AS). Adult patients ≥18 yr w/ chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
Dosage/Direction for Use
SC Adult 18-64 yr & elderly ≥65 yr RA, PsA & AS 25 mg twice wkly or 50 mg once wkly. PsO 25 mg twice wkly or 50 mg once wkly. Alternatively 50 mg twice wkly for up to 12 wk followed, if necessary, by 25 mg twice wkly or 50 mg once wkly. Continue for up to 24 wk until remission is achieved. Paed Juvenile idiopathic arthritis 0.4 mg/kg (up to max: 25 mg/dose) twice wkly w/ 3-4 day interval between doses or 0.8 mg/kg (up to max: 50 mg/dose) once wkly. Paed PsO (≥6 yr) 0.8 mg/kg (up to max: 50 mg/dose) once wkly for up to 24 wk.
Hypersensitivity. Sepsis or risk of sepsis. Active infections including chronic or localised infections.
Special Precautions
Discontinue if serious infection or allergic reactions occur. Patients w/ history of repeated infectious diseases or latent diseases easily leading to infection; heart failure. Repeated upper resp tract infection. Anti-infection & anti-tumor therapy. Live vaccines is not recommended during therapy. Women of childbearing potential should use appropriate contraception during therapy & for 3 wk thereafter. Not recommended for use in pregnant & lactating women. Childn ≤2 yr. Elderly.
Adverse Reactions
Infections including upper resp tract infections, bronchitis, cystitis, skin infections; inj site reactions including bleeding, bruising, erythema, itching, pain, swelling. Allergic reactions, autoAb formation; pruritus; fever.
Drug Interactions
Higher rate of serious infections & neutropenia w/ anakinra. Increased serious adverse events w/ abatacept (not recommended). Decreased WBC counts w/ sulfasalazine.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
ATC Classification
L04AB01 - etanercept ; Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
Etveza powd for inj 25 mg
2 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in